News Quantified

MEIP – mei pharma, inc. (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

MEI Pharma, Inc. Rebrands as Lite Strategy, Inc., Adopts New NASDAQ Ticker ‘LITS’

MEI Pharma (NASDAQ:MEIP) was downgraded by analysts at Wall Street Zen

Form 3 Lite Strategy, Inc. For: Sep 09 Filed by: Schornstein Alexander

Form SCHEDULE 13G/A Lite Strategy, Inc. Filed by: Schornstein Alexander

Form 8-K MEI Pharma, Inc. For: Sep 10

Form EFFECT MEI Pharma, Inc.

Form 424B3 MEI Pharma, Inc.

Top News Gainers

4/14 MEI Pharma and Kyowa Kirin Announce Global License, Development and Commercialization Agreement for ME-401 51.5%

3/31 MEI Pharma Announces Fast Track Designation Granted by U.S. FDA for ME-401 For the Treatment of Adult Patients with Relapsed or Refractory Follicular Lymphoma 13.4%

3/20 Form 8-K MEI Pharma, Inc. For: Mar 18 11.3%

9/9 Form 4 MEI Pharma, Inc. For: Sep 06 Filed by: White Christine Anna 9.8%

12/26 MEI Pharma Inc (NASDAQ: MEIP) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 7.8%

2/14 Form SC 13G/A MEI Pharma, Inc. Filed by: PERCEPTIVE ADVISORS LLC 7.7%

4/27 MEI Pharma Set To Explode With Announcement Of Lucrative Partnership [Seeking Alpha] 6.0%

12/18 Form 424B5 MEI Pharma, Inc. 5.8%

5/15 MEI Pharma to Present New Clinical Results on ME-401 and ME-344 Programs at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting 5.8%

11/1 MEI Pharma Inc (NASDAQ: MEIP) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $2.00 price target on the stock. 5.0%

Top News Decliners

3/23 MEI Pharma Inc (NASDAQ: MEIP) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. -30.6%

12/16 MEI Pharma Announces Proposed Public Offering of Common Stock -25.2%

4/14 Form 8-K MEI Pharma, Inc. For: Apr 13 -18.0%

10/3 MEI Pharma +16.7% on updated early-stage trial data [Seeking Alpha] -15.8%

12/27 MEI Pharma: A $2 Biotech Concern With 9 Lives [Seeking Alpha] -7.8%

12/24 MEI Pharma Inc (NASDAQ: MEIP) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. -6.4%

9/25 Form SC 13G/A MEI Pharma, Inc. Filed by: PERCEPTIVE ADVISORS LLC -6.3%

2/6 Q2/2020 12/31/2019 EPS -0.260 ZacksConsensus -0.180 ActVsEst (0.080) - Miss -5.7%

11/19 MEI Pharma Inc (NASDAQ: MEIP) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -4.3%

2/12 MEI Pharma Inc (NASDAQ: MEIP) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $2.75 price target on the stock. -4.2%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day